- 专利标题： FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT
-
申请号： EP21883129.5申请日： 2021-10-14
-
公开(公告)号： EP4234578A1公开(公告)日： 2023-08-30
- 发明人: KIM, Soyoun , YOO, Jae Do , JEON, In Seon , KIM, Min-Seong , LEE, Byung-Heon
- 申请人： Kyungpook National University Industry-Academic Cooperation Foundation
- 申请人地址： KR Daegu 41566 (Kyungpook National University, Sangyeok-dong) 80, Daehak-ro, Buk-gu,
- 代理机构： Roos, Peter
- 优先权： KR20200138075 20201023
- 国际公布： WO2022086058 20220428
- 主分类号： C07K16/18
- IPC分类号： C07K16/18 ; C07K7/06 ; C07K14/47 ; C12N15/62 ; A61K9/51 ; A61K31/704 ; A61P35/00
摘要：
The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.
信息查询
